European Commission logo
English English
CORDIS - EU research results

Development of a novel low dose, high resolution, high contrast X-ray detector for medical applications to improve patient diagnoses and reduce the risk of X-radiation induced cancer


X-ray imaging is a valuable medical diagnostic technique, accounting for 47% of the medical imaging market in 2011. However, current X-ray detection technology exposes patients to increased risk of developing cancer with research in 13 developing countries showing that exposure to X-ray detection technology accounted for 0•6% to 1•8% of the cancer cases. X-ray detector manufacturers are thus keenly seeking technology that would reduce radiation exposure (dose) to patients whilst offering superior material discrimination for earlier detection and treatment of clinical cases.
As IBEX, we have developed and patented an innovative X-ray detection technology incorporating our unique Multi Absorption Plate (MAP). Our technology significantly surpasses current solutions based on cadmium telluride (CdTe) as it offers potential dose reduction of >50% plus enhanced materials discrimination. MAP-Detector offers a disruptive X-ray detector that will leverage the MAP technology in both retrofitted and new build X-ray detectors for medical applications.
The global medical diagnostic imaging market is expected to grow from €21.4bn in 2012 to €27.4bn by 2017, with X-ray and CT imaging equipment having a 50%/€13.1bn share in 2017. Within this segment, the X-ray imaging detector market is estimated at €2.0bn. Our technology will be compatible with the leading X-ray inspection systems creating significant market potential. Our initial target segments within the medical industry are fluoroscopy and mammography with dosage reduction being far more important for the former and materials discrimination an essential requirement for the latter.
In Phase 1 we will thoroughly analyse the market to more clearly define our route to market and requirements for rapid market uptake. This will culminate in the drafting of a more detailed operational business plan.
In Phase 2 we intend to conduct clinical trials and achieve certification for our technology in preparation for market introduction.

Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 50 000,00
United Kingdom

See on map


The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

North East (England) Tees Valley and Durham Durham CC
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Total cost
€ 71 429,00